Healthcare is entering a golden age of innovation, with genetic sequencing and other advanced technologies enabling a rapid pace of medical breakthroughs
At the same time, demand for care is growing as populations age and unmet medical needs persist. These dynamics are creating sizable growth opportunities - with potentially positive outcomes for patients and investors alike. Janus Henderson's healthcare strategy draws on deep scientific expertise to invest across pharmaceuticals, biotechnology, medical devices, and healthcare services, seeking long-term risk-adjusted returns in one of the most dynamic sectors in global equity markets.
Investment opportunities in healthcare for investors
Demographics
Between 2015 and 2050, the proportion of the world’s population over 60 years will nearly double from 12% to 22%*. This, coupled with globalisation and population growth around the world, is a natural, persistent tailwind for the healthcare sector.
* World Health Organization, Ageing and health, 1 October 2025.
Technology and AI
Innovation is crucial for investing in healthcare. Companies with groundbreaking medical products that improve patient care or meet unmet needs have achieved returns, even as the broader market has struggled. Examples include improved med tech devices and robotics for surgical procedures.
Mergers and acquisitions (M&A)
M&A is an important feature of the healthcare landscape, offering a pathway for innovative biotech companies to see long-term potential recognised earlier, underpinned by strong balance sheets and continued pipeline demand across large-cap pharma.
Our healthcare funds are designed to:
Identify healthcare's best scientific and commercial opportunities
Focus on small- and mid-cap biotech companies, aiming to maximise the sector's growth potential
Mitigate downside risk through a proprietary value-at-risk framework
How to integrate healthcare in my investment portfolio?
"Investors who have added health care to their global equity portfolio would have experienced superior risk-adjusted returns."
Sabrina Denis
Senior Associate Director, Investment Specialist
Why invest in healthcare with Janus Henderson?
Over 125 years' experience
Janus Henderson's healthcare investment team includes 3 PhDs and 1 MD, with over 125 years of combined experience in healthcare investing.
20+ year healthcare strategy now available as an OEIC
Healthcare has historically shown the widest performance gap between top- and bottom-performing stocks of any equity sector. Our long-term, risk/reward-focused approach is designed to navigate this dispersion.
A long-term approach
Deep fundamental research, a disciplined long-term framework, and a specialist investment team set Janus Henderson apart in pursuing superior risk-adjusted returns in healthcare.
Insights
Meet our healthcare investment team
Portfolio Manager, Global Life Sciences Strategy
In the field of healthcare investing since 2007
Portfolio Manager, Global Life Sciences Strategy
In the field of healthcare investing since 2000
Portfolio Manager, Biotechnology Strategy
In the field of healthcare investing since 2014
View broader team
Vish Sridharan, MD
Biotechnology
Luyi Guo, PhD, CFA
Pharmaceuticals
Tim McCarty, CFA
Medical Technology
Important information
Please read the following important information regarding these funds.
